NCT04802746View on ClinicalTrials.gov

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

November 22, 2021

Study Completion Date

November 22, 2021

Conditions
Healthy Study ParticipantsParticipants With Mild Asthma
Interventions
DRUG

Alprazolam

Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.

OTHER

Placebo

Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.

Trial Locations (2)

27607

Up0099 102, Raleigh

02747

Up0099 101, North Dartmouth

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04802746 - A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma | Biotech Hunter | Biotech Hunter